Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection in non-cirrhotic, treatment-naïve patients; Treat non-cirrhotic treatment-naïve patients with HCV genotype 2, 4, 5 and 6 infection
Regulatory Designation U.S. - Breakthrough Therapy (Treat chronic HCV genotype 1 infection)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today